Study guide
13.4 Adrenal Insufficiency & Endocrine Hypertension
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
13.4 Adrenal Insufficiency & Endocrine Hypertension
Key Takeaways Explain This Topic AI
Adrenal crisis is treated with immediate intravenous hydrocortisone 100 mg and fluid resuscitation; treatment must not wait for the short Synacthen test.
Primary hyperaldosteronism is screened with the aldosterone:renin ratio and typically causes hypertension with hypokalaemic metabolic alkalosis.
Phaeochromocytoma is screened with plasma or 24-hour urinary metanephrines, and alpha blockade with phenoxybenzamine must precede beta blockade to avoid unopposed alpha stimulation.
Last updated: September 2026
- 2. Adrenal Insufficiency & Acute Addisonian Crisis
- Primary vs. Secondary Adrenal Insufficiency
Adrenal insufficiency denotes deficiency of adrenocortical hormones. Pathophysiological and clinical differentiation is critical:
Feature Primary Adrenal Insufficiency (Addison's) Secondary / Tertiary Adrenal Insufficiency
Anatomical Level Adrenal cortex (destruction of all 3 zones) Pituitary gland (secondary) or Hypothalamus / steroid withdrawal (tertiary)
Etiology Autoimmune adrenalitis ( 80 % 80\% 80% in UK; 21-hydroxylase Abs), Tuberculosis ( 10 % 10\% 10% ), Bilateral adrenal haemorrhage, Metastases Pituitary adenomas, craniopharyngioma, hypophysectomy, abrupt cessation of chronic glucocorticoid therapy
Glucocorticoids (Cortisol) Deficient Deficient
Mineralocorticoids (Aldosterone) Deficient (renin-angiotensin axis destroyed at end-organ) Preserved (RAAS intact and regulated by renal perfusion/K+)
Adrenal Androgens (DHEA-S) Deficient Deficient
Cutaneous Pigmentation Marked hyperpigmentation (palmar creases, buccal mucosa, scars, axillae) due to lack of cortisol negative feedback driving POMC and α \alpha α -MSH synthesis Absent (pale, 'alabaster' skin; ACTH and POMC are low)
Electrolyte Disturbances Hyponatraemia AND Hyperkalaemia ; hyperchloraemic normal anion gap metabolic acidosis Hyponatraemia alone (dilutional due to cortisol deficiency impairing free water clearance); potassium is normal
Plasma ACTH Markedly elevated ( > 100 – 200 pg/mL > 100\text{–}200\text{ pg/mL} > 100 – 200 pg/mL ) Inappropriately low or low-normal
Diagnostic Evaluation of Adrenal Insufficiency
Random / Morning Serum Cortisol (08:00–09:00): Cortisol < 100 nmol/L < 100\text{ nmol/L} < 100 nmol/L strongly suggests adrenal insufficiency; cortisol > 450 – 500 nmol/L > 450\text{–}500\text{ nmol/L} > 450 – 500 nmol/L excludes it; intermediate values mandate dynamic testing.
Short Synacthen Test (SST): The definitive diagnostic investigation. Synthetic ACTH 1–24 ( 250 mcg 250\text{ mcg} 250 mcg tetracosactide) is administered IM or IV; serum cortisol is measured at 0, 30, and 60 minutes. A normal response is a peak cortisol > 450 – 500 nmol/L > 450\text{–}500\text{ nmol/L} > 450 – 500 nmol/L . Failure to achieve this threshold confirms adrenal insufficiency.
Plasma ACTH: Differentiates primary (high) from secondary (low) insufficiency.
Adrenal Autoantibodies: Anti-21-hydroxylase antibodies are positive in > 85 % > 85\% > 85% of autoimmune Addison's disease (isolated or within Autoimmune Polyendocrine Syndrome Type 1 [APS-1: AIRE gene mutation; candidiasis, hypoparathyroidism, Addison's] or Type 2 [APS-2: HLA-DR3/DR4; Addison's, autoimmune thyroid disease, type 1 diabetes]).
Chronic Replacement Regimen
Glucocorticoid Replacement: Hydrocortisone 15 – 25 mg 15\text{–}25\text{ mg} 15 – 25 mg total daily dose, divided into 2 or 3 doses mimicking normal circadian physiology (e.g. 10 mg 10\text{ mg} 10 mg on waking, 5 mg 5\text{ mg} 5 mg at midday, 2.5 – 5 mg 2.5\text{–}5\text{ mg} 2.5 – 5 mg late afternoon; avoiding evening doses that provoke insomnia).
Mineralocorticoid Replacement: Fludrocortisone 50 – 200 mcg 50\text{–}200\text{ mcg} 50 – 200 mcg once daily in the morning (required only in primary adrenal insufficiency). Dose titrated against sitting and standing blood pressure (avoiding postural drop), serum sodium, potassium, and plasma renin activity.
Sick Day Rules: Patients must be educated to double their oral hydrocortisone dose during intercurrent febrile illness, carry a steroid emergency card and medical alert bracelet, and possess an emergency intramuscular hydrocortisone ( 100 mg 100\text{ mg} 100 mg ) injection kit for vomiting or severe trauma.
Emergency Management of Acute Addisonian Crisis
An acute adrenal crisis is an immediately life-threatening emergency precipitated by infection, trauma, surgery, or medication non-compliance in an individual with primary or secondary hypoadrenalism. Presents with shock, refractory hypotension, severe vomiting, acute abdominal pain ('pseudo-peritonitis'), fever, and profound hypoglycaemia.
Immediate Hydrocortisone: Administer intravenous hydrocortisone 100 mg stat bolus , followed by 100 – 200 mg 100\text{–}200\text{ mg} 100 – 200 mg per 24 hours (either as a continuous IV infusion or 50 mg 50\text{ mg} 50 mg IV every 6 hours). Never delay hydrocortisone administration to perform diagnostic testing!
Rapid Volume Resuscitation: Infuse intravenous 0.9% normal saline ( 1 L 1\text{ L} 1 L over the first hour, running 3 to 4 liters over 24 hours) to restore intravascular volume and correct hyponatraemia. If hypoglycaemia is present, administer intravenous 10 % 10\% 10% dextrose.
Identify & Treat Precipitants: Send blood cultures and administer empirical broad-spectrum antibiotics if infection is suspected.
Fludrocortisone Note: Fludrocortisone is NOT required acutely ; at doses > 50 mg/day > 50\text{ mg/day} > 50 mg/day , hydrocortisone exhibits maximal, saturating cross-reactivity at the mineralocorticoid receptor.
- 3. Endocrine Hypertension
- Primary Aldosteronism (Conn's Syndrome)
Autonomous, renin-independent aldosterone overproduction represents the most common surgically curable cause of secondary hypertension ( 5 – 10 % 5\text{–}10\% 5 – 10% of all hypertensives, rising to > 20 % > 20\% > 20% in resistant hypertension):
Etiology: Bilateral idiopathic adrenal hyperplasia (60–65%) vs. Unilateral aldosterone-producing adenoma (APA / Conn's adenoma, 30–35%) ; rare causes include unilateral adrenal hyperplasia and glucocorticoid-remediable aldosteronism (GRA / Familial Hyperaldosteronism Type 1, chimeric C Y P 11 B 1 / C Y P 11 B 2 CYP11B1/CYP11B2 C Y P 11 B 1/ C Y P 11 B 2 gene).
Pathophysiology: Excess aldosterone activates mineralocorticoid receptors in principal cells of the renal cortical collecting duct, upregulating epithelial sodium channels (ENaC) and basolateral Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase. This drives sodium retention and intravascular expansion (suppressing renin), accompanied by potassium excretion via ROMK channels and hydrogen ion secretion via intercalated cell H + \text{H}^+ H + -ATPase. This yields hypertension, hypokalaemia , and metabolic alkalosis . Note: > 50 % > 50\% > 50% of patients with primary aldosteronism are normokalaemic at presentation!
Screening Test: Aldosterone-to-Renin Ratio (ARR): Measured morning in an upright, seated, non-stressed patient. Elevated plasma aldosterone concentration (PAC) with profoundly suppressed plasma renin activity (PRA) or direct renin concentration (DRC). An ARR > 30 – 50 > 30\text{–}50 > 30 – 50 (depending on laboratory units) is positive. Medication washout: Mineralocorticoid receptor antagonists (spironolactone, eplerenone) and amiloride must be stopped for at least 6 weeks; ACE inhibitors, ARBs, and beta-blockers must be stopped for 2 weeks. Alpha-blockers (doxazosin) and verapamil have minimal impact on ARR and are used for interim blood pressure control.
Confirmatory Testing: Saline infusion test ( 2 L 2\text{ L} 2 L 0.9 % 0.9\% 0.9% saline over 4 hours) or oral sodium loading; failure of aldosterone to suppress below 140 nmol/L 140\text{ nmol/L} 140 nmol/L confirms autonomy.
Subtype Differentiation: High-resolution CT of the adrenals to visualize morphology, followed by Adrenal Vein Sampling (AVS) . AVS is the mandatory gold standard to distinguish unilateral adenoma from bilateral hyperplasia in surgical candidates, because non-functioning incidental adrenal cortical adenomas are common and can lead to inappropriate adrenalectomy.
Management:
Unilateral Adenoma: Laparoscopic unilateral adrenalectomy (cures hypokalaemia in 100 % 100\% 100% and cures or improves hypertension in > 80 % > 80\% > 80% ).
Bilateral Hyperplasia: Medical therapy with mineralocorticoid receptor antagonists: Spironolactone ( 25 – 100 mg 25\text{–}100\text{ mg} 25 – 100 mg once daily). In men developing gynaecomastia, mastodynia, or erectile dysfunction, switch to the selective MRA Eplerenone ( 50 – 100 mg 50\text{–}100\text{ mg} 50 – 100 mg daily).
Phaeochromocytoma & Paraganglioma
Catecholamine-producing neuroendocrine tumors arising from chromaffin cells of the adrenal medulla (phaeochromocytoma, 80 – 85 % 80\text{–}85\% 80 – 85% ) or extra-adrenal sympathetic paraganglia (paraganglioma, 15 – 20 % 15\text{–}20\% 15 – 20% ):
Classical 'Rule of 10s' (Traditional Teaching): 10 % 10\% 10% bilateral, 10 % 10\% 10% extra-adrenal (organ of Zuckerkandl, carotid body), 10 % 10\% 10% malignant (defined strictly by distant metastases to non-chromaffin tissue), and 10 % 10\% 10% familial. However, modern genetic profiling shows that > 30 – 40 % > 30\text{–}40\% > 30 – 40% of all cases harbor germline mutations : MEN2A and MEN2B ( RET proto-oncogene), Von Hippel-Lindau ( VHL ), Neurofibromatosis type 1 ( NF1 ), and succinate dehydrogenase subunit mutations ( SDHB [high malignancy risk], SDHD ).
Clinical Presentation: Paroxysmal triad of headache ( 80 % 80\% 80% ) , profuse diaphoresis ( 70 % 70\% 70% ) , and palpitations ( 65 % 65\% 65% ) , accompanied by severe episodic or sustained hypertension, anxiety/panic attacks, pallor, tremor, and orthostatic hypotension.
Biochemical Diagnosis: First-line screening is measurement of 24-hour urinary fractionated metanephrines or plasma free metanephrines (sensitivity > 97 – 99 % > 97\text{–}99\% > 97 – 99% ). Catecholamines are metabolized intratumorally by catechol-O-methyltransferase (COMT) into metanephrines and normetanephrines, which are released continuously, avoiding the false-negative results of pulsatile parent catecholamine surges.
Imaging: Contrast-enhanced CT or MRI of abdomen/pelvis. Functional imaging with iodine-123 metaiodobenzylguanidine (123I-MIBG) or gallium-68 DOTATATE PET-CT for metastatic, recurrent, or paraganglionic disease.
Preoperative Medical Preparation (CRITICAL EXAM PEARL):
α \alpha α -Blockade FIRST, then β \beta β -Blockade SECOND:
Non-competitive α \alpha α -adrenergic blockade with oral Phenoxybenzamine (starting at 10 mg 10\text{ mg} 10 mg twice daily and uptitrated over 10 to 14 days) or selective α 1 \alpha_1 α 1 -blockers (doxazosin). Generous salt and fluid intake are prescribed concurrently to expand the contracted intravascular volume.
β \beta β -Blockers (e.g. propranolol, bisoprolol) are added ONLY AFTER full, effective α \alpha α -blockade is established (evidenced by orthostatic drop and nasal congestion), to control reflex tachycardia.
The Cardinal Rule: NEVER administer a β \beta β -blocker alone or prior to complete α \alpha α -blockade! Blocking vasodilator β 2 \beta_2 β 2 receptors in the presence of uninhibited α 1 \alpha_1 α 1 stimulation provokes catastrophic, uncontrolled systemic vasoconstriction, precipitating fatal hypertensive crises, intracranial haemorrhage, or acute pulmonary oedema.